文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

连续性血液净化对脓毒症患者免疫及内皮细胞功能的影响

[Effect of continuous blood purification on immunity and endothelial cell function in patients with sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2023-01-01
一句话结论CVVH可改善脓毒症患者免疫抑制和内皮损伤标志物,但未降低28天死亡风险或缩短ICU住院时间。

一项前瞻性研究纳入滨州医学院附属医院重症医学科2019年3月至2020年10月收治的年龄≥18岁、符合脓毒症诊断标准的患者,随机分为标准治疗组(20例)和CBP治疗组(19例)。两组均按2016年国际脓毒症和脓毒性休克管理指南给予标准治疗,CBP组额外接受CVVH(剂量25-30 mL×kg-1×h-1,血流速150-200 mL/min,每日>20小时,共3天)。治疗3天后,CBP组乳酸、PCT、APACHE II评分、SOFA评分较治疗前显著降低,IFN-γ、IL-4、PD-1、IL-7、sTM、SDC-1、HS等指标改善程度优于标准治疗组,淋巴细胞计数显著高于标准治疗组;但两组ICU住院时间及28天死亡人数无显著差异。

要点

  • CVVH剂量25-30 mL×kg-1×h-1、血流速150-200 mL/min、每日>20小时、共3天,可改善脓毒症患者免疫抑制和内皮损伤标志物。
  • 治疗3天后CBP组淋巴细胞计数高于标准治疗组(×10^9/L:1.3±0.3 vs. 0.9±0.4,P<0.05)。
  • 治疗3天后CBP组IL-4、IFN-γ、IFN-γ/IL-4比值、IL-7、PD-1、sTM、SDC-1、HS、Ang-2均显著低于标准治疗组(均P<0.05)。
  • 两组ICU住院时间[(10±5)天 vs.(9±4)天]及28天死亡人数(5例 vs. 8例)无显著差异(均P>0.05)。
  • 治疗前及治疗1天后两组各指标均无显著差异。

适用人群与场景

  • 年龄≥18岁、符合脓毒症诊断标准、收入重症医学科的患者。

处置流程与药物剂量

  • 两组均按2016年国际脓毒症和脓毒性休克管理指南给予标准治疗,包括初始液体复苏、感染源控制和抗生素治疗。
  • CBP治疗组在标准治疗基础上加用连续性静脉-静脉血液滤过(CVVH),剂量25-30 mL×kg-1×h-1,血流速150-200 mL/min,每日治疗时间>20小时,共3天。

研究设计与关键结果

  • 前瞻性研究,最终纳入标准治疗组20例、CBP治疗组19例;两组性别、年龄、感染部位无显著差异。
  • 标准治疗组ICU住院时间(10±5)天,28天死亡5例、存活15例;CBP治疗组ICU住院时间(9±4)天,28天死亡8例、存活11例;两组ICU住院时间和28天死亡人数无显著差异(均P>0.05)。
  • 治疗前及治疗1天后,两组乳酸、PCT、淋巴细胞计数、APACHE II评分、SOFA评分及免疫功能和内皮细胞损伤相关指标均无显著差异。
  • 治疗3天后,CBP组乳酸、PCT、APACHE II评分、SOFA评分较治疗前显著降低,IFN-γ、IL-4、PD-1、IL-7、sTM、SDC-1、HS等较治疗前显著改善,改善程度优于标准治疗组。
  • 治疗3天后CBP组淋巴细胞计数显著高于标准治疗组(×10^9/L:1.3±0.3 vs. 0.9±0.4,P<0.05)。
  • 治疗3天后CBP组IL-4(ng/L)2.8(1.5,3.2)vs. 标准治疗组3.3(2.7,5.2),IFN-γ(ng/L)6.3(5.4,106.5)vs. 217.9(71.4,517.1),IFN-γ/IL-4比值3.7(1.8,70.3)vs. 59.1(18.3,124.9),IL-7(ng/L)4.6(3.2,5.1)vs. 6.3(5.2,8.0),PD-1(μg/L)0.04(0.03,0.06)vs. 0.08(0.05,0.12),sTM(μg/L)4.9(4.3,7.4)vs. 8.7(6.0,10.8),SDC-1(μg/L)0.6(0.3,1.1)vs. 0.9(0.8,2.5),HS(ng/L)434.8(256.2,805.0)vs. 887.9(620.1,957.3),Ang-2(ng/L)934.0(673.3,1502.1)vs. 2233.9(1

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,CBP治疗可消除脓毒症患者的免疫抑制状态、减少多种内皮损伤标志物及糖萼降解,但不能降低28天死亡风险或缩短ICU住院时间。

指南或共识出处

  • 2016年国际脓毒症和脓毒性休克管理指南。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the effect of continuous blood purification (CBP) on the immunity and endothelial cell function of patients with sepsis.

METHODS: A prospective study was conducted. The patients aged ≥ 18 years old and meeting the diagnostic criteria of sepsis admitted to the department of critical care medicine of Binzhou Medical University Hospital from March 2019 to October 2020 were selected as the research subjects, and the patients were divided into standard treatment group and CBP treatment group according to random number table method. Both groups were given standard treatment including initial fluid resuscitation, infection source control and antibiotics according to the 2016 international guidelines for the management of sepsis and septic shock. CBP treatment group was additionally given continuous veno-venous hemofiltration (CVVH) at a dose of 25-30 mL×kg-1×h-1 and blood flow rate of 150-200 mL/min for more than 20 hours a day for 3 days. The clinical data of patients including blood lactic acid (Lac), procalcitonin (PCT), lymphocyte count (LYM), acute physiology and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score were recorded before treatment and 1 day and 3 days after treatment. At the same time, the venous blood was collected, and the immune function related indexes [interleukins (IL-4, IL-7), programmed death receptor-1 (PD-1), programmed death ligand-1 (PD-L1), interferon-γ (IFN-γ)] and endothelial cell injury related markers [soluble thrombomodulin (sTM), angiopoietin-2 (Ang-2), von Willebrand factor (vWF), heparan sulfate (HS), syndecan-1 (SDC-1)] levels in serum were determined by enzyme-linked immunosorbent assay (ELISA). The length of intensive care unit (ICU) stay of patients in the two groups was recorded, and the outcomes of patients in the two groups were followed up for 28 days.

RESULTS: Finally, 20 patients were enrolled in the standard treatment group, and 19 patients were enrolled in the CBP treatment group. There were no significant differences in gender, age and infection site between the two groups. The length of ICU stay in the standard treatment group was (10±5) days, and 5 patients died and 15 patients survived after 28 days. The length of ICU stay in the CBP treatment group was (9±4) days, and 8 patients died and 11 patients survived after 28 days. There were no significant differences in the length of ICU stay and number of patients who died within 28 days between the two groups (both P > 0.05). There were no significant differences in the Lac, PCT, LYM, APACHE II score, SOFA score and immune function and endothelial cell injury related indexes before treatment and 1 day after treatment between the two groups. After 3 days of treatment, the Lac, PCT, APACHE II score and SOFA score of the CBP treatment group were significantly lower than those before treatment, and pro-inflammatory and anti-inflammatory cytokines such as IFN-γ and IL-4, apoptosis-related indicators such as PD-1 and IL-7, and endothelial injury related factors such as sTM, SDC-1 and HS were significantly improved compared with the pre-treatment, the improvement degree of the above indicators was more obvious than that of the standard treatment group, and LYM was significantly higher than that of the standard treatment group (×109/L: 1.3±0.3 vs. 0.9±0.4, P < 0.05), IL-4, IFN-γ, IFN-γ/IL-4 ratio, IL-7, PD-1, sTM, SDC-1, HS, and Ang-2 were significantly lower than those of the standard treatment group [IL-4 (ng/L): 2.8 (1.5, 3.2) vs. 3.3 (2.7, 5.2), IFN-γ (ng/L): 6.3 (5.4, 106.5) vs. 217.9 (71.4, 517.1), IFN-γ/IL-4 ratio: 3.7 (1.8, 70.3) vs. 59.1 (18.3, 124.9), IL-7 (ng/L): 4.6 (3.2, 5.1) vs. 6.3 (5.2, 8.0), PD-1 (μg/L): 0.04 (0.03, 0.06) vs. 0.08 (0.05, 0.12), sTM (μg/L): 4.9 (4.3, 7.4) vs. 8.7 (6.0, 10.8), SDC-1 (μg/L): 0.6 (0.3, 1.1) vs. 0.9 (0.8, 2.5), HS (ng/L): 434.8 (256.2, 805.0) vs. 887.9 (620.1, 957.3), Ang-2 (ng/L): 934.0 (673.3, 1 502.1) vs. 2 233.9 (1 472.5, 3 808.4)], the differences were statistically significant (all P < 0.05).

CONCLUSIONS: CBP treatment can eliminate the patient's immunosuppressive state, reduce a variety of endothelial injury markers and the degradation of glycocalyx, but cannot decrease the 28-day death risk or shorten the length of ICU stay.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Chen Y, Huang X, Liu X, et al. [Effect of continuous blood purification on immunity and endothelial cell function in patients with sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 36916374. doi:10.3760/cma.j.cn121430-20220110-00037

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。